Canada - TSX-V:THRM - CA8834262070 - Common Stock
The current stock price of THRM.CA is 0.075 CAD. In the past month the price decreased by -25%. In the past year, price decreased by -76.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PRN.CA | PROFOUND MEDICAL CORP | N/A | 222.59M | ||
| MIR.CA | MEDMIRA INC | N/A | 64.46M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 52.03M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 45.28M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 28.51M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 22.39M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 20.67M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 18.45M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 18.11M | ||
| IDL.CA | IMAGING DYNAMICS CO LTD | N/A | 309.90K | ||
| VVTM.CA | VVT MED INC | N/A | 21.38M |
Therma Bright, Inc. engages in developing and marketing skin care medical device products. The company is headquartered in Toronto, Ontario. The company went IPO on 2001-07-11. The firm is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on three key strategic areas: respiratory disease, vascular health and consumer medical devices. Its respiratory disease portfolio includes AI4LYF Digital Cough Technology and InStatin-novel inhaled treatment for asthma and COPD. Its vascular disease portfolio includes Inretio-ischemic stroke treatment and Venowave-Deep Vein Thrombosis Treatment Device (DVT). Its consumer health portfolio consists of AcuVid Covid-19 Rapid Antigen Saliva Test, Benepod-Contrast Therapy Device, TheroZAP-Thermal Therapy Device and InterceptCS-Cold Sore Prevention System. The firm holds trademarks for Therozap, InterceptCS and AcuVid.
THERMA BRIGHT INC
345 Danforth Avenue
TORONTO ONTARIO M4M 3P1 CA
CEO: Rob Fia
Employees: 0
Phone: 18442746837
Therma Bright, Inc. engages in developing and marketing skin care medical device products. The company is headquartered in Toronto, Ontario. The company went IPO on 2001-07-11. The firm is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on three key strategic areas: respiratory disease, vascular health and consumer medical devices. Its respiratory disease portfolio includes AI4LYF Digital Cough Technology and InStatin-novel inhaled treatment for asthma and COPD. Its vascular disease portfolio includes Inretio-ischemic stroke treatment and Venowave-Deep Vein Thrombosis Treatment Device (DVT). Its consumer health portfolio consists of AcuVid Covid-19 Rapid Antigen Saliva Test, Benepod-Contrast Therapy Device, TheroZAP-Thermal Therapy Device and InterceptCS-Cold Sore Prevention System. The firm holds trademarks for Therozap, InterceptCS and AcuVid.
The current stock price of THRM.CA is 0.075 CAD.
THRM.CA does not pay a dividend.
THRM.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on THRM.CA.
THERMA BRIGHT INC (THRM.CA) currently has 0 employees.
ChartMill assigns a technical rating of 1 / 10 to THRM.CA. When comparing the yearly performance of all stocks, THRM.CA is a bad performer in the overall market: 96.29% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to THRM.CA. THRM.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months THRM.CA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS increased by 19.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.59% | ||
| ROE | -261.64% | ||
| Debt/Equity | 0.04 |